Duchenne Muscular Dystrophy Treatment Market Analysis

Distribution Channel Segment Analysis

In terms of distribution channel, hospital pharmacies dominate the segment and are expected to have the revenue share of 65.5% in the Duchenne muscular dystrophy treatment market over the assessed period. The segment is driven by the critical role in healthcare facilities in administering complex DMD curatives, which require specialized medical supervision. Moreover, the importance of these settings in managing progressive neuromuscular disorders due to the availability of multidisciplinary financial support and ongoing therapeutic monitoring helps this segment outperform home-based treatment options.

Treatment Type Segment Analysis

Based on treatment type, the gene therapy segment is expected to dominate the Duchenne muscular dystrophy treatment market by 2035. The dominance of the segment can be characterized by its worldwide acceptance as the gold standard first-line DBD therapy. Based on the evidence in June 2023, Indiana University received USD 3.8 million for research in gene therapies and also tested alternative forms of treatment for degenerative diseases such as duchenne muscular dystrophy. The increased R&D investment highlights the innovation in the treatment of DMD.

Route of Administration Segment Analysis

The intravenous (IV) is the largest sub-segment in the route of administration segment. The dominance is due to the need for biologics such as antisense oligonucleotides (e.g., eteplirsen, golodirsen) and gene therapies to be administered systemically. According to the Clinical Trial Register in 2025, almost 44358 clinical trials are conducted in duchenne muscular dystrophy. In addition, advanced DMD clinical trials overwhelmingly utilized IV infusion, reflecting its critical role in ensuring precise dosing and bioavailability for these complex and high-cost therapeutics. 

Our in-depth analysis of the duchenne muscular dystrophy treatment market includes the following segments: